Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;

KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;

KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;